<DOC>
	<DOCNO>NCT01207011</DOCNO>
	<brief_summary>The study evaluate effect amrubicin ( AMR ) compare docetaxel ( DOC ) treatment non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Amrubicin ( AMR ) Trial Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Histological cytological diagnosis nonsmall cell lung cancer ( NSCLC ) 1 2 prior chemotherapy regimen include 1 platinumbased chemotherapy 20 old young 75 year age Symptomatic brain metastasis Interstitial pneumonia pulmonary fibrosis Abnormal cardiac function myocardial infraction within 6 month study enrollment Active infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>